Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, …
Industry Peers
Drug Manufacturers - General| Headline | Source | Time |
|---|---|---|
Older | ||
 Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. | ||
 Organon (OGN) Lags Q2 Earnings Estimates Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Sun Pharma's quarterly profit jumps on strength in specialty medicines By Kashish Tandon July 31 (Reuters) - India's Sun Pharmaceutical Industries reported a 27% rise in first-quarter profit on Friday, driven by robust growth in its high-margin specialty medicines | ||
 Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | ||
 Organon & Co. Shareholders Clear Sun Pharma Merger Deal Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons | ||
 Organon (OGN) Names A Canada Chief, Is The Stock Cheap? Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors’ radar after Organon Canada appointed Dominic Bégin as President and Managing Director, a leadership move that could influence how the company prioritizes its Canadian growth plans. See our latest analysis for Organon. For context, Organon’s share price is US$13.52, with a 90 day share price return of 57.21% and an 86.74% year to date share price return. The 3 year total shareholder return has declined... | ||
 Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. | ||
IInsider Monkey | ||